Pertinently to the topic of this review, clinical trials for KRAS mutant PDAC with momelotinib, were unsuccessful [140], despite being effective in reducing tumor burden in a KrasLSLG12D/WT–induced lung cancer model [287]. This evidence concerns the gene KRAS and neoplasm.